Senju Pharma has launched a new drug for dry eye disease (DED) in Japan, Avarept, which is the first drug in the TRPV1 antagonist class to reach the market. Licensed from fellow Japanese drugmaker ...

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...

Mission Therapeutics of the UK has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, ...

In the biggest venture capital financing this week, clinical-stage radiopharmaceutical AdvanCell has closed a $315 million ...

All 15-year-old children in the UK should be offered the vaccine against meningitis B (MenB) in the wake of fatal outbreaks ...

MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval in the US, after getting the go-ahead ...

At the moment, many of the big AI systems used in drug discovery are closed-source, meaning they are proprietary and carry an ...

For decades, pharmaceutical marketing has been built on a simple premise: if we present the right data, to the right audience ...

Fresh from signing an alliance with Novartis, Chai Discovery has raised $400 million in a third-round financing to support ...

Thousands of people in England and Wales with a type of chronic heart failure (CHF) could soon be eligible for treatment with ...

The European Commission has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, making it the first oral ...

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia Therapeutics and Braveheart Bio the ...